<DOC>
	<DOCNO>NCT00856401</DOCNO>
	<brief_summary>The purpose protocol add additional exploratory study investigate change bone quality parameter PTH ( 1-84 ) treatment hypoparathyroidism . In addition biochemical hallmark hypoPT , find microscopic structure bone , well bone remodel system , markedly abnormal disease . How abnormality may correct PTH ( 1-84 ) administration fully understood . The study outline add-on protocol design shed light mechanistic way PTH ( 1-84 ) replacement may restore normal bone metabolism . These mechanistic study beyond scope parent NPS study , design assess safety efficacy PTH ( 1-84 ) hypoPT treatment . Subjects participate NPS ' REPLACE , RELAY , RACE Studies HEXT Study Columbia University invite participate add-on protocol , involve separate IRB-approved informed consent . Study procedure : 1 . High Resolution Peripheral Quantitative Computed Tomography ( HRpQCT ; XtremeCT , Scanco ) : Done visit DXA . In REPLACE study twice , RELAY ( do within last 6 month ) , RACE twice , HEXT three time . 2 . Osteolineage : At Baseline/Randomization/Visit One 4 , 8 , 12 , 24 , 52 week treatment REPLACE , RELAY , RACE Study , applicable , baseline 6-months visit HEXT Study , blood test circulate osteogenic cell ( 10 cc ) perform 3 . Sclerostin : At Baseline/Randomization/Visit One 4 , 8 , 12 , 24 , 52 week treatment REPLACE , RELAY , RACE Study , applicable , baseline 6-months visit HEXT Study , blood test sclerostin ( 5cc ) perform Funding Source - FDA OOPD</brief_summary>
	<brief_title>ADD-ON Study Existing Hypoparathyroidism Studies</brief_title>
	<detailed_description>In protocol , investigate mechanism PTH ( 1-84 ) treatment improve bone quality patient hypoparathyroidism . Detailed imaging , cellular biochemical study perform subject hypoparathyroidism also participate NPS Pharmaceutical Company 's study know REPLACE , RELAY , RACE study , IND70449 's HEXT Study . The parent NPS trial , conduct NPS 's IND # 76,514 , multi-site , randomize , double-blind , placebo-controlled trial PTH ( 1-84 ) hypoparathyroidism . In REPLACE Study , hypoparathyroid subject assign either placebo , 50 , 75 100 mcg PTH ( 1-84 ) day , dose-titration design , 26 week period . In RELAY Study hypoparathyroid patient randomize 25mcg 50mcg PTH1-84 8 week . In RACE Study hypoparathyroid patient utilize 25 , 50 , 75 , 100mcg PTH1-84 52 week . The primary efficacy endpoint 50 % reduction calcium calcitriol supplementation . The Columbia site one investigative sit NPS protocol . A letter NPS accompany document certifies Dr. Bilezikian subinvestigator NPS project . The protocol describe proposal different NPS study . It conduct IND # 70,449 Dr. Bilezikian . It pursue number additional study sponsor NPS cover IND . Under IND # 70,449 assign Dr. Bilezikian , investigate effect PTH ( 1-84 ) administration hypoparathyroidism bone quality hypoparathyroidism . In addition biochemical hallmark hypoparathyroidism , find microarchitectural structure bone entire bone remodel system markedly abnormal disease . The study outline add-on protocol design elucidate specific way PTH ( 1-84 ) replacement restore normal bone microstructure bone metabolism hypoparathyroidism . These mechanistic study beyond scope parent NPS study , design assess safety efficacy PTH ( 1-84 ) hypoparathyroidism . These special study conduct Dr. Bilezikian 's group Columbia . In summary provide , present three major study conduct . PROTOCOL # 1 : THE EFFECT OF PTH ( 1-84 ) ADMINISTRATION ON SKELETAL MICROSTRUCTURE AS DETERMINED BY HIGH RESOLUTION IMAGING OF THE SKELETON . [ ( PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY ( HR-PQCT ) ) . Protocol . For subject enrol Columbia site , perform HR-pQCT . Baseline measurement obtain twice Visit 4 NPS protocol ( 2 week prior randomization ) Visit 16 NPS protocol ( final injection day ) . The reason duplicate measurement time point minimize variance , thus improve accuracy data obtain . Anticipated Results . Based upon preliminary data , expect abnormality observe baseline subject hypoparathyroidism improve administration PTH ( 1-84 ) . The improvement skeletal microstructure associate great bone strength determine finite element analysis individual assignment strength specific orientation trabecular plate rod forearm tibia . In addition , remarkable abnormality cortical structure specific focus attention , particularly view fact disease characterize excessive secretion PTH ( primary hyperparathyroidism ) , cortical thinning observe . Thus , add-on protocol , able test hypothesis PTH regulate spatial distribution cortical trabecular bone . This anticipated result add great value protocol give u insight would otherwise possible make . PROTOCOL # 2 : THE EFFECT OF PTH ( 1-84 ) ADMINISTRATION ON OSTEOBLAST CELLS AS DETERMINED BY MEASUREMENT OF CIRCULATING OSTEOGENIC PRECURSORS Protocol . For subject enrol NPS protocol Columbia site , perform measurement peripheral circulate osteoblast cell . The assay perform Visit 5 ( randomization ) NPS Protocol , 4 , 8 , 12 , 24 week administration PTH ( 1-84 ) . Anticipated Results . Based upon preliminary observation , expect PTH ( 1-84 ) stimulate recruitment , circulation , cell osteoblastic phenotype . We expect PTH ( 1-84 ) also stimulate maturation cell define ligand marker date chronological age cell . The ability demonstrate specific osteoblastic effect circulate cell correlate change structural parameter obtain patient use HR-pQCT . PROTOCOL # 3 : THE EFFECT OF PTH ( 1-84 ) ADMINISTRATION ON SCLEROSTIN , A KEY MEDIATOR OF PTH 'S OSTEOANABOLIC ACTIONS . Protocol . We measure sclerostin level Visit 5 ( randomization ) NPS Protocol , 4 , 8 , 12 , 24 week post-randomization . This first time ever sclerostin level measure hypoparathyroid subject replace PTH ( 1-84 ) . Anticipated Results . We expect administration PTH ( 1-84 ) subject hypoparathyroidism associate acute reduction sclerostin . By virtue experimental design study , able test kinetics change , namely whether anticipate acute fall sclerostin level sustain time . The result related cellular action PTH recruit activate osteogenic cell conduct Protocol # 2 well osteoanabolic effect expect demonstrate Protocol # 1. . GENERAL STUDY FEATURES RELATED TO ALL PROTOCOLS Enrollment Eligibility Criteria . The enrollment criterion follow protocol sponsor NPS IND . They provide Appendix request . Study subject enrol NPS study automatically eligible protocol describe constitute study population additional study . We expect enroll 16 patient remain three year grant period . Safety Measures . The safety measure conduct identical NPS protocol sponsor IND # 76,514 . They provide Appendix request . They send office Dr. Mary Parks . Overall Summary Significance . These add-on protocol do uniquely Columbia site sponsorship IND # 70449 assign Dr. Bilezikian . They hold promise defining , way possible standard protocol sponsor NPS , mechanism PTH ( 1-84 ) therapeutic subject hypoparathyroidism . Funding Source - FDA OOPD</detailed_description>
	<mesh_term>Hypoparathyroidism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>active participation CL111040 , PARC10007 PARC10008 Studies sponsor NPS Pharmaceuticals . active participation HEXT Study Dr. John Bilezikian . participant CL111040 , PARC10007 PARC10008 Studies sponsor NPS Pharmaceuticals HEXT Study Dr. John Bilezikian .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>hypoparathyroidism</keyword>
	<keyword>hypopara</keyword>
	<keyword>PTH</keyword>
	<keyword>parathyroid hormone</keyword>
	<keyword>CL-11-040</keyword>
	<keyword>CL1-11 Study</keyword>
	<keyword>NPSP 558</keyword>
	<keyword>RELAY</keyword>
	<keyword>RACE</keyword>
	<keyword>REPLACE</keyword>
	<keyword>HEXT</keyword>
	<keyword>c10-007</keyword>
	<keyword>c10-008</keyword>
	<keyword>NPSP558</keyword>
	<keyword>Columbia study</keyword>
	<keyword>Columbia study</keyword>
	<keyword>HPTH</keyword>
	<keyword>PTH1-84</keyword>
</DOC>